Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$702.47M$702.47M+13.3% vs Q3 2023 Net Income-$156.00K-$156.00KN/M vs Q3 2023 EPS Diluted$0.00$0.00−100.0% vs Q3 2023 Gross Profit$269,558,000+15.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$141,774,000+74.2% Free Cash Flowderived$124,829,000+79.0% Margins · derivedGross margin38.4%+0.9 pt vs Q3 2023
Operating margin12.6%+0.4 pt vs Q3 2023
Net margin-0.0%−1.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end